-
|
Benzinga –
12:22 PM ET 06/15/2022
Wednesday's session saw 269 companies set new 52-week lows. Here are all the stocks that set new 52-week lows on Wednesday: Be sure to monitor Benzinga for the news traders need!
|
-
|
GlobeNewswire –
8:00 AM ET 06/09/2022
InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention System for the prevention of stroke, today provided the following highlights from multiple presentations and live case transmission, all featuring its CGuard Embolic Prevention Stent System, from LINC 2022, which was held June 6-9.
|
-
|
Benzinga –
4:09 AM ET 06/06/2022
Some of the stocks that may grab investor focus today are: Check out our premarket coverage here
|
-
|
Reuters –
4:19 PM ET 06/03/2022
InspireMD Inc (NSPR): * INSPIREMD INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Further company coverage:
|
-
|
GlobeNewswire –
8:00 AM ET 06/02/2022
InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention System for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course 2022, which is being held June 6-9 in Leipzig, Germany.
|
-
|
Benzinga –
12:28 PM ET 05/11/2022
On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.
|
-
|
Benzinga –
8:00 AM ET 05/10/2022
InspireMD reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:30 AM. Here's what investors need to know about the announcement. InspireMD beat estimated earnings by 28.75%, reporting an EPS of $-0.57 versus an estimate of $-0.8. Revenue was up $177.00 thousand from the same period last year.
|
-
|
Reuters –
7:31 AM ET 05/10/2022
InspireMD Inc (NSPR): * INSPIREMD REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.57. * Q1 REVENUE ROSE 17.6 PERCENT TO $1.183 MILLION Source text for Eikon: Further company coverage:
|
-
|
GlobeNewswire –
7:30 AM ET 05/10/2022
- 20% growth in CGuard revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard clinical advantages - - European logistics hub established with BOMI Group for direct market access as well as establishing...
|
-
|
Benzinga –
5:18 AM ET 05/10/2022
MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. ** Target Hospitality is projected to report earnings for its first quarter. ** Hudson Global is projected to report earnings for its first quarter. ** Maiden Hldgs is estimated to report earnings for its first quarter. ** WhiteHorse Finance is likely to report earnings for its first quarter.
|
-
|
GlobeNewswire –
7:30 AM ET 04/28/2022
InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2022 financial results on Tuesday, May 10, 2022, before the market opens.
|
-
|
GlobeNewswire –
4:05 PM ET 03/16/2022
InspireMD, Inc. (NSPR), a global developer of the CGuard Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leader webinar on its CGuard Stent Platform and its MicroNet portfolio on Tuesday, March 22, 2022 at 2 p.m. Eastern Time.
|
-
|
GlobeNewswire –
7:30 AM ET 03/08/2022
- CGuard Revenue Generated 87.5% growth over Q420 and 55.9% Year-over-Year - - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Authority - - CGuard Included as Carotid Stent Treatment Option in National Institute of Neurological Disorders and Stroke Sponsored CREST-2 Trial...
|
-
|
GlobeNewswire –
7:00 AM ET 02/28/2022
- CGuard Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke and actively engaged at more than 140 study locations - TEL AVIV, Israel, Feb. 28, 2022 -- InspireMD, Inc. (NSPR), a global developer of the CGuard Embolic Prevention Stent System device ...
|
-
|
GlobeNewswire –
4:30 PM ET 02/22/2022
-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announces it will report fourth quarter and full year 2021 financial results on Tuesday, March 8, 2022, before the market opens.
|
-
|
GlobeNewswire –
8:00 AM ET 02/15/2022
InspireMD, Inc. (NSPR), a global developer of the CGuard Embolic Prevention Stent System device for the treatment of Carotid Artery Disease and stroke prevention, today announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Companys Scientific Advisory Board.
|
-
|
GlobeNewswire –
8:00 AM ET 01/27/2022
InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention Stent System for prevention of stroke caused by Carotid Artery Disease, today announced that Marvin Slosman, Chief Executive Officer, is scheduled to present at the IAGS Biennial Scientific Meeting being held from January 31 February 3, 2022 in Punta Cana, Dominican Republic.
|
-
|
GlobeNewswire –
8:11 AM ET 01/18/2022
InspireMD, Inc. (NSPR), developer of the CGuard Embolic Prevention Stent System for prevention of stroke caused by Carotid Artery Disease, today announced that a live case demonstration featuring CGuard EPS will be broadcasted at the International Symposium on Endovascular Therapy 2022 Conference by Dr. Chris Metzger, Chair of Clinical Research at Ballad Health on Tuesday, January 18, 2022.
|
Page:
|
Today's and Upcoming Events
-
NSPR to announce Q2 earnings (Unconfirmed)
Past Events (last 90 days)
-
NSPR announced Q1 earnings.
Data provided by Thomson Reuters © 2022
|